Immunogen Inc (DELISTED) (IMGN:DL)
31.23
0.00 (0.00%)
USD |
NASDAQ |
Feb 13, 16:00
Immunogen Cash from Financing (TTM): 495.80M for Sept. 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
September 30, 2023 | 495.80M |
June 30, 2023 | 464.12M |
March 31, 2023 | 26.97M |
December 31, 2022 | 27.55M |
September 30, 2022 | 280.71M |
June 30, 2022 | 321.65M |
March 31, 2022 | 321.59M |
December 31, 2021 | 355.74M |
September 30, 2021 | 173.72M |
June 30, 2021 | 132.46M |
March 31, 2021 | 132.54M |
December 31, 2020 | 195.74M |
September 30, 2020 | 100.60M |
June 30, 2020 | 100.54M |
March 31, 2020 | 100.79M |
December 31, 2019 | 2.873M |
September 30, 2019 | 2.169M |
June 30, 2019 | 2.192M |
March 31, 2019 | 164.62M |
December 31, 2018 | 166.81M |
September 30, 2018 | 267.39M |
June 30, 2018 | 265.94M |
March 31, 2018 | 102.87M |
December 31, 2017 | |
September 30, 2017 |
Date | Value |
---|---|
June 30, 2017 | |
March 31, 2017 | |
September 30, 2016 | |
June 30, 2016 | 101.77M |
March 31, 2016 | 202.11M |
December 31, 2015 | 202.04M |
September 30, 2015 | 202.88M |
June 30, 2015 | 198.56M |
March 31, 2015 | 2.011M |
December 31, 2014 | 3.397M |
September 30, 2014 | 5.255M |
June 30, 2014 | 9.136M |
March 31, 2014 | 10.36M |
December 31, 2013 | 10.23M |
September 30, 2013 | 7.348M |
June 30, 2013 | 98.02M |
March 31, 2013 | 99.19M |
December 31, 2012 | 99.74M |
September 30, 2012 | 100.97M |
June 30, 2012 | 6.988M |
March 31, 2012 | 93.79M |
December 31, 2011 | 92.32M |
September 30, 2011 | 91.30M |
June 30, 2011 | 90.70M |
March 31, 2011 | 79.19M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
2.169M
Minimum
Sep 2019
495.80M
Maximum
Sep 2023
179.88M
Average
132.50M
Median
Cash from Financing (TTM) Benchmarks
AbbVie Inc | -211.00M |
Pfizer Inc | 26.07B |
Johnson & Johnson | -21.42B |
Merck & Co Inc | -5.57B |
Cerevel Therapeutics Holdings Inc | 548.62M |